Key statistics dashboard for CDT Equity Inc. (CDT). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company’s pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto’s thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clin...
Stock Data
| Price | $0.20 |
| Market Cap | $0M |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | 0.00 |
| Price / Book | 0.01 |
| P/S | 0.00 |
| P/FCF | -0.07 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 38.65% |
| EBIT Margin | 12.10% |
| EBITDA Margin | 16.82% |
| Operating Margin | 11.55% |
| Net Margin | 6.30% |
Financial Health
| Current Ratio | 2.14 |
| Quick Ratio | 1.49 |
| Cash Ratio | 0.53 |
| Debt / Equity | 0.95 |
| Debt / Assets | 37.64% |
| Interest Coverage | -6.20 |
Per-Share Data
| Revenue per share | 37.20 |
| Book Value per share | 35.60 |
| Cash per share | 8.97 |
| FCF per share | -0.03 |
| Tangible Book Value per share | -0.68 |
| Dividend per share | 0.00 |
Related companies: CCM · COCH · ENVB · HEPA · LIXT · NIVF · PTPI
Explore sector: Healthcare · Biotechnology
More sections of CDT: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks